[Experience with suprofen for acute and chronic pain in neurologic practice]

A single-dose, double-blind study included a total of 196 patients with neurologic pain. The subjects were subdivided into five groups and treated with alpha-methyl-4-(2-thienylcarbonyl) benzene acetic acid (suprofen, Suprol) 400 mg; suprofen 200 mg acetylsalicylic acid (ASA) 650 mg; ASA 650 plus codeine 60 mg; and placebo. The population was homogeneous as to age, sex, and body weight. About 95% of the patients rated the intensity of pain severe prior to treatment. The clinical effect was appreciated by investigator and patients after up to 6 h following administration of the single dose. It was demonstrated that the active substances all were significantly superior to placebo in all criteria tested. Statistical analysis of the parameters investigated revealed the following order of effectiveness of the test medications: Suprofen 400 and 200, respectively, = ASA 650 + codeine 60 greater than ASA 650 greater than placebo. The final overall patients appreciation of effectiveness showed good to very good results in 97.4% of the patients on suprofen 400; 65% of those on suprofen 200; 72.5% of those on ASA 650 + codeine 60; 13.5% of those on ASA 650; and 7.5% of those on placebo. During the treatment 26 patients experienced adverse reactions; of these, 18 subjects on ASA 650 + codeine 60 complained of fatigue or somnolence as the side effect experienced most frequently.